

Date: November 22, 2024

To,

The Manager
Listing Department
National Stock Exchange (NSE)
Exchange Plaza, 5th Floor
Plot No. C/1, G-Block
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051
Symbol: SAGILITY

The Manager
Listing Department
Bombay Stock Exchange (BSE)
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
Scrip Code:544282

Dear Sir/Ma'am,

Subject: Intimation of investors call pursuant to Regulation 30(6) read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, investor/analyst webinar for discussing the unaudited financial results of the Company for quarter and half year ended 30th September 2024 will be held on Wednesday, 27th November 2024 at 4:00PM (IST). The details of the call are provided as an annexure to this letter.

The details are also being made available on the Company's website www.sagilityhealth.com

This is for your kind information and record

Thanking You,

For Sagility India Limited

Sarvabhousman Doraiswamy Srinivasan
Group Chief Financial Officer

Encl:a/a

Sagility India Limited

(Formerly Sagility India Private Limited; earlier Berkmeer India Private Limited)

Registered Office - No. 23 & 24, AMR Tech Park, Building 2A, First Floor Hongasandara Village, Off Hosur Road, Bommanahalli, Bengaluru – 560068, Karnataka, India

Corporate Identity Number: U72900KA2021PLC150054

Tel. No.: 080-71251500, Website: www.SagilityHealth.com



Sagility India Ltd.

Q2 & H1 FY25 Earnings Webinar Wednesday, November 27, 2024, at 04:00 PM IST

Bengaluru, November 22 2024 — Sagility India Limited (SAGILITY), a technology-enabled, pure-play healthcare focused solutions and services provider, will host its earnings webinar for analysts and investors on Wednesday, November 27, 2024 at 04:00 PM IST. The call will commence with an introduction of the business, followed by operational and financial highlights for the quarter and half year ending September 30, 2024. There is an interactive Question & Answer session planned after the presentation.

The Company will be represented by

- Mr. Ramesh Gopalan – Managing Director and Group CEO
- Mr. Sarvabhoutman Srinivasan – Group Chief Financial Officer

Dial-in details are as follows:

Timing	04:00 PM IST on Wednesday, November 27, 2024
Pre-registration Link	Sagility – Q2 FY25 Concall Registration Link

- **Platform:** Zoom. Please download the latest app for your device: [Download Link](#).
- **Pre-Registration:** Mandatory. Register up to 3 hours before the call using the provided link.
- **Q&A Session:** After management's commentary, participants may join the queue by clicking the “Raise Hand” icon during the commentary. When announced, unmute yourself using the “Unmute Me” button to ask your question.

About Sagility India Limited.

Sagility is a technology-enabled, healthcare-focused solutions and services provider that supports U.S.-based payers, providers, and their partners in delivering best-in-class operations, enhancing member and provider experiences, and improving the quality of care, all while ensuring cost-effective financial and clinical outcomes.

With over two decades of experience, Sagility's dedicated experts address complex healthcare challenges through deep domain expertise and innovative thinking. The company serves five of the top ten health insurance companies in the U.S., utilizing its advanced technology, processes, and solutions to ensure efficient operations and minimize additional administrative costs. The Company delivers these services through its skilled talent pool across five global service delivery centers located in India, the Philippines, the U.S., Jamaica, and Colombia.

For more information, please visit www.sagilityhealth.com OR contact:

Mr. Abhishek Kayan

Sagility India Limited

Email: investorservices@sagilityhealth.com

Siddharth Rangnekar

CDR India

Email: siddharth@cdr-india.com

Safe Harbor:

Certain statements made in this call concerning our future growth prospects may be interpreted as forward-looking statements, which involve a number of risks and uncertainties that could cause the actual results to differ materially from those in such forward-looking statements. Investors are requested to use their discretion in relying on them. We do not undertake to update any forward-looking statements that may be made from time to time.